Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)

Background: The TROFEO trial demonstrated that febuxostat causes greater and more rapid reduction of serum uric acid (s-UA) than topiroxostat. We compared these drugs in patients with chronic kidney disease (CKD) by sub-analysis of the TROFEO trial. Methods: This sub-analysis targeted patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sezai, Akira, Unosawa, Satoshi, Taoka, Makoto, Osaka, Shunji, Sekino, Hisakuni, Tanaka, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435131/
https://www.ncbi.nlm.nih.gov/pubmed/31748427
http://dx.doi.org/10.5761/atcs.oa.19-00162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435131/
https://www.ncbi.nlm.nih.gov/pubmed/31748427
http://dx.doi.org/10.5761/atcs.oa.19-00162

Ejemplares similares